Ann: Trading Halt, page-245

Kaken sold ~ 35,000 units in the first two months of sales..... so 40,000 in a quarter is definatly " underselling it " given USA has 3x the population, 3.7 million of which are seeking treatment.

Every 100,000 units sold per year is around 66 cents per share price using a 36xP/E ( similar to CSL - 200 profit based on 750 sales price )

If they do 40,000 in a quarter -> annualized is 160,000 so around $1.14 should the SP with a 36 PE.

Kaken sales direct BOT PE 36 share price.

First 2 months 34,867 units
Next year 194,911 units.......... Bot share price $1.38
Next year 257,899 units.......... Bot share price $1.82
Last year 350,000 units .......... Bot share price $2.47

3 x US population adjustment, and 2 x script average adjustment
First 2 months 209,202 units
Next year 1,169,446 units.......... Bot share price $8.34



Definately worth sticking around to see if the US population and the increased script renewal rocket sales.
BOT will fly under the radar until the first sales figures come in, and then all will be revealed!

Matching Japan demographics / population adjusted / average script renewal adjusted .... should be over a million units per year right out of the gate.